Daniel H. Farkas, PhD
Daniel H. Farkas, PhD, HCLD (ABB), CC, CLSp(MB), FACB, is Vice President, Clinical Diagnostics at the Sequenom Center for Molecular Medicine in Grand Rapids, Michigan, a molecular diagnostics laboratory committed to maternal fetal medicine testing. Previously, Dr. Farkas was Executive Director of the Center for Molecular Medicine in Grand Rapids, a 21st century genomics initiative that was a joint venture of Spectrum Health and the Van Andel Institute. Dr. Farkas has established three hospital-based molecular diagnostics laboratories (St. Barnabas Medical Center in Livingston, NJ; Beaumont Hospital, Royal Oak, MI; and The Methodist Hospital, Houston, TX) and done two stints in the biotechnology industry. Dr. Farkas, a member since 1990, has served AACC in the following capacities: AMOC Chair, 2006 (member of 2000 and 2003 AMOCs); Outstanding Speaker Award, 2000; Chair, SDCOC (1995; 2000-2001); Chair, Molecular Pathology Division, 1995; Member of the following committees and groups: Nominations (2002-2003); Meetings Management Group (2000 and 2003-2006); Government Relations (1997-2001); and Clinical Laboratory News Board of Editors (1995-1999); Liaison to CAP Molecular Pathology Resource Committee (1996-2004); Member, NACB Editorial Board for PGx LMPG. Dr. Farkas was the first professional certified by the American Board of Bioanalysis in Molecular Diagnostics (1996) and now serves on ABB's board. Dr. Farkas was President of the Association for Molecular Pathology in 2003 and has served as a consultant to the FDA Clinical and Molecular Genetics Devices Panel. He has been on the faculties of Michigan State University (MSU; current), Baylor College of Medicine, Weill Medical College of Cornell University and Beaumont Hospital's Medical Technology program. Dr. Farkas earned a BS degree in Microbiology and Public Health from MSU and a PhD in Cellular and Molecular Biology from the State University of New York at Buffalo.